Table IV.

Predicted hospitalizations in 12 months following initiation of atypical antipsychotic therapy under various therapeutic scenarios

Scenario	Average annual number of hospitalizations (95% CI)	% change from Status quo	p-value
Status quo	1.83 (1.81–1.85)	–	–
All patients started on branded group of AADs	1.73 (1.59–1.87)	−5.5	0.15
All patients started on generic group of AADs	2.07 (1.91–2.23)	13.1	0.001
All patients started on optimal predicted therapy	1.32 (1.26–1.40)	−27.9	<0.001

AAD, atypical antipsychotic drug.

Notes: p-values reflect comparisons of average annual number of hospitalizations under various scenarios to status quo.

Branded group of AADs include ziprasidone, quetiapine, and aripripazole. Generic groups of AADs include risperdione and olanzapine.